Related Experiment Video
Updated: Feb 20, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Pharmacotherapy for Irritable Bowel Syndrome
Michael Camilleri1, Alexander C Ford2
1Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.) and Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905, USA. camilleri.michael@mayo.edu.
Irritable bowel syndrome (IBS) is a brain-gut axis disorder. Current and emerging IBS pharmacotherapies offer options for bowel dysfunction, but significant unmet needs for pain management remain.
Area of Science:
- Gastroenterology
- Neurogastroenterology
- Pharmacology
Background:
- Irritable bowel syndrome (IBS) is a complex functional gastrointestinal disorder.
- Pathophysiology involves the brain-gut axis, including motility, neurohormonal, immune, and epithelial factors.
- Significant unmet needs exist for effective IBS treatments, especially for pain management.
Purpose of the Study:
- To review current pharmacotherapy for IBS, including mechanisms, efficacy, and safety.
- To discuss medications in phase III trials for IBS treatment.
- To highlight the ongoing need for improved IBS therapies.
Main Methods:
- Literature review of current and investigational IBS pharmacotherapies.
- Analysis of mechanisms of action, clinical trial data, and safety profiles.
- Synthesis of information on drugs targeting secretion, motility, and gut microbiota.
Main Results:
- Current pharmacotherapies address bowel dysfunction in IBS through various mechanisms.
- Several new medications targeting IBS pathophysiology are in late-stage clinical trials.
- Effective pain management remains a critical challenge in IBS treatment.
Conclusions:
- Pharmacological options for IBS bowel dysfunction have expanded.
- Further research and development are crucial to address the unmet need for pain relief in IBS.
- A comprehensive approach to IBS management is essential.
More Related Videos
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Irritable Bowel Syndrome III: Medical and Nursing Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

